Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Sean PlattonChristina HuntPublished in: International journal of laboratory hematology (2018)
This small study suggests that it is likely that DOAC Stop can be used in laboratories to screen for coagulopathy or lupus anticoagulants in samples containing rivaroxaban or apixaban. Care should be taken in the interpretation of results since complete reversal of the anti-Xa effect did not occur in every sample.
Keyphrases
- venous thromboembolism
- atrial fibrillation
- direct oral anticoagulants
- end stage renal disease
- pulmonary embolism
- healthcare
- ejection fraction
- high throughput
- systemic lupus erythematosus
- chronic kidney disease
- newly diagnosed
- palliative care
- peritoneal dialysis
- quality improvement
- rheumatoid arthritis
- disease activity
- health insurance